Adding dendritic cell-immunotherapy for post-transplant hepatocellular carcinoma recurrence

Area of Science:

• Oncology
• Immunotherapy
• Transplantation

Background:

• Hepatocellular carcinoma (HCC) recurrence post-liver transplant often presents as multiple, extrahepatic disease with poor prognosis.
• Current treatments for post-transplant HCC recurrence have limited efficacy.
• Investigating novel therapeutic strategies is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of adding dendritic cell (DC) immunotherapy to tyrosine kinase inhibitors for treating post-transplant HCC recurrence.
• To compare survival rates between patients receiving combination therapy and those treated with tyrosine kinase inhibitors alone.

Main Methods:

• A cohort of 11 patients received tyrosine kinase inhibitors plus DC-immunotherapy (2020-2024).
• DCs were generated from peripheral blood monocytes and pulsed with tumor lysate.
• A historical control group of 23 patients treated with tyrosine kinase inhibitors only (2009-2020) was used for comparison.

Main Results:

• The combination therapy group showed significantly improved 1-, 2-, and 3-year survival rates (70.7%, 40.4%, 40.4%) compared to the control group (52.5%, 17.4%, 8.7%; p=0.050).
• Nine patients (81.8%) achieved stable disease, while two (18.2%) had progressive disease.
• No adverse effects were attributed to DC immunotherapy.

Conclusions:

• Dendritic cell immunotherapy is a safe treatment modality for liver transplant recipients experiencing HCC recurrence.
• The addition of DC-immunotherapy to standard treatment regimens can potentially prolong survival in select patients with post-transplant HCC recurrence.